TX-MARY-KAY
7.1.2022 23:15:07 CET | Business Wire | Press release
Mary Kay Inc., a global entrepreneurship development company and advocate for corporate social responsibility and sustainability, today released its year-end highlights. In 2021, Mary Kay Inc. continued its decades-long commitment to enriching the lives of women around the globe and building healthier, more sustainable communities.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220107005500/en/
Learn more about Mary Kay’s 2021 accomplishments in this report .
2021 YEAR-END HIGHLIGHTS
Business Excellence
- Mary Kay received 58 awards and recognition honors in 2021, including: COVID Response (22 awards), recognition from partners in social impact/annual reports (4), Mary Kay management recognized for leadership (7), business excellence (10) and an award-winning documentary (4 awards; 5 screening selections). Additionally, Mary Kay and/or its iconic founder, Mary Kay Ash, were featured in two Harvard Business Case Studies, three textbooks, and one research paper.
- Announced the appointment of Wendy Wang as President of its Asia Pacific Region . 54% of Mary Kay’s global executive team is female.
- Mary Kay markets celebrated anniversaries: Mary Kay Lithuania (10 years) and Mary Kay Germany (35 years).
- Named one of America's Best Mid-Sized Employers 2021 by Forbes .
Mary Kay Global Design Studio & Digital Innovation to Enhance the Customer Experience
- Mary Kay Global Design Studio and Glamhive announced the first-ever global TikTok reality show based on style, Step & Repeat . The contest showcased talent in wardrobe, makeup & hair from TikTok users worldwide. Participants showcased their talents from more than 30 countries, and the ground-breaking campaign was featured in the UK Daily Mail , The Daily Front Row , and Vogue Business highlighting its innovative approach to using the relatively new social media platform.
- Launched Suite 13 , a beauty experience that uses virtual reality to digitize the company's first virtual pop-up showroom; Mary Kay MirrorMe™ for augmented-reality makeovers and Mary Kay® Skin Analyzer App to scan your face for a customized skin care routine.
- Celebrated 25 years partnering with Global Beauty Ambassador, Luis Casco.
Science Behind the Beauty
- Clinical Solutions™ skincare launched, which consists of Mary Kay Clinical Solutions™ Retinol 0.5 and Mary Kay Clinical Solutions™ Calm + Restore Facial Milk and received the Dermatologists’ Council Seal.
- Dr. Michelle Hines, Ph.D., Mary Kay Director of Product Formulation, was announced as president-elect for the Society of Cosmetic Chemists (SCC).
- In collaboration with Society for Investigative Dermatology (SID), announced Skin Health/Skin Disease Grants. Grants will be awarded to researchers conducting groundbreaking, innovative studies in skin health and skin diseases to uncover new perspectives and intervention strategies.
- Announced recipients of multiple science educational grants including: the Society of Cosmetic Chemists and Mary Kay Inc. - Madam C.J. Walker Scholarships, in support of under-represented minority students pursuing an undergraduate or graduate degree in chemical, physical, medical, pharmaceutical, biological, or related sciences and technology; and provided five Girls in STEAM grants to young women currently engaged in innovative research. The 2021 recipients included: Mylana Brodovska, Ukraine; Selin Alara Ornek, Turkey; Jordan Reeves, U.S.; Ivanna Hernandez, Colombia; and Allie Weber, U.S.
- Unveiled research at multiple virtual science conferences. The research included: sharing research on a gradual retinization process that significantly improves tolerance to higher concentrated pure retinol , while still delivering retinol’s key skin benefits; presented the findings for topical application of pure retinol improving hyperpigmentation in an Asian population; and Modulating mechanisms associated with skin barrier function effectively alleviates 2 common concerns associated with sensitive skin.
Social Impact/CSR
- In 2021, Mary Kay’s global Pink Changing LivesSM cause empowerment program supported over 15 NGOs around the world. Since 2008, the program has impacted more than six million women and their families by partnering with over 3,000 organizations, donating over $16 million.
- Mary Kay China: China's Henan province was affected by severe flooding. Due to the floods, at least 33 people were killed, 8 others went missing, 200,000 people were evacuated, 3 million people were affected, and the direct economic loss was about $1.22 billion yuan. Mary Kay China donated 1-million-yuan worth of products to Henan Charity Federation.
- Mary Kay Germany: European floods impacted Germany, Austria, Belgium and the Netherlands and ranked as the most destructive natural hazard in Northern Europe. Mary Kay Germany pledged up to $100,000 euros to support those affected.
- Mary Kay Spain: In 2020-21, partnered with the Fundación Vicente Ferrer to provide health care access to children and their families in India. Prior to the COVID-19 pandemic (in 2018), Mary Kay Spain financed the construction of a school for children in Pagadalavaripalli village, located in the Kadiri (Anantapur) region of India.
Women’s Empowerment
- Announced commitment to advancing gender parity by releasing a position paper welcoming the European Commission’s Gender Equality Strategy for 2020 – 2025 and by joining the Generation Equality Forum in Paris and five Global Action Coalitions to accelerate gender equality by 2026.
- In collaboration with UN Women, ILO & WE Empower, re-released, “Strengthening Support for Women Entrepreneurs in COVID-19 Response and Recovery ” at the Commission on the Status of Women (CSW65).
- Mary Kay and the Mary Kay Ash FoundationSM were recognized in the Report of the United Nations Entity for Gender Equality and the Empowerment of Women on the activities of the United Nations trust fund in support of actions to eliminate violence against women to the Commission on the Status of Women (CSW65) and Human Rights Council.
Diversity, Equity & Inclusion (DEI)
- Announced 100% of U.S.-based Directors and above completed mandatory Unconscious Bias training.
- Released Gender Diversity in the Workplace Data: 54% of Mary Kay’s global executive team is female; 61% of Mary Kay’s global workforce is female; and 54% of Global Vice Presidents and above are female; 59% of Directors and above are female.
- In collaboration with global partner Equal Rights Trust, announced the launch of innovative research on gender inequality in algorithms and artificial intelligence aimed at addressing equality and gender impacts of algorithmic systems, presented by Mary Kay.
Sustainability
- Announced global sustainability strategy: Enriching Lives Today for a Sustainable Tomorrow . Our holistic approach encompasses three pillars of sustainability—economic, environmental and social—through five pillars, activated by 15 commitments to deliver a decade of sustainable action.
- Became a signatory to two crucial causes in protecting our world’s waterways: the CEO Water Mandate and the United Nations Global Compact’s Sustainable Ocean Principles.
- Joined the Ellen MacArthur Foundation as a member of its Network, as part of its commitment to becoming a more sustainable, circular business.
- Mary Kay released its second documentary, Forest of Hope , in October during the 2021 UN Climate Change Conference (COP26) . The documentary highlights the work of Angelica, a 70-year eco-warrior and leader of a group of women entrepreneurs committed to saving the forests of Monterrey.
- Through its partnership with Arbor Day Foundation, the Time for Trees® initiative, announced achieving the commitment to planting 100 million trees and inspiring 5 million new tree planters by April of 2022, was achieved one year ahead of schedule.
- Mary Kay has partnered with the Nature Conservancy since 1991. In 2021, Mary Kay supported seven projects in the Solomon Islands, Northern Australia, New Zealand, rural China, Mexico, the United States, and Canada.
About Mary Kay
One of the original glass ceiling breakers, Mary Kay Ash founded her beauty company nearly 60 years ago with three goals: develop rewarding opportunities for women, offer irresistible products, and make the world a better place. That dream has blossomed into a multibillion-dollar company with millions of independent sales force members in nearly 40 countries. Mary Kay is dedicated to investing in the science behind beauty and manufacturing cutting-edge skin care, color cosmetics, and fragrances. Mary Kay is committed to empowering women and their families by partnering with organizations from around the world, focusing on supporting cancer research, protecting survivors from domestic abuse, beautifying our communities, and encouraging children to follow their dreams. Mary Kay Ash’s original vision continues to shine—one lipstick at a time. Learn more at www.MaryKayGlobal.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20220107005500/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
2PointZero Group Signals Global Scale With Revenue Surge to AED 21.9 Billion and Net Profit of AED 7.7 Billion in H1 202631.7.2026 13:42:00 CEST | Press release
Group revenue growth supported by stable gross profit margin of 29%, and adjusted EBITDA of AED 5.0 billionGlobal expansion milestones include the completed sale of TAQA stake, and the acquisition of Traverse Midstream Partners in North America, Baobab Group in Africa, and 60.8% of ISEM in ItalyTIME ranks the Group 36th on the World’s Growth Leaders list for 2026, highlighting market stability, operational scale and disciplined approach to capital 2PointZero Group (ADX: 2POINTZERO), a leading Abu Dhabi-based investment holding firm, announced its financial results for the first half of 2026, reporting revenue of AED 21.9 billion and delivering a Group Net Profit of AED 7.7 billion. This robust performance is reflected in the Group’s adjusted EBITDA, which reached AED 5.0 billion after excluding fair value changes and one-offs. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260731538982/en/ Samia Bouazza, CEO of 2PointZero (P
Datroway® Approved in the EU as Only TROP2 Directed Medicine with Overall Survival Benefit for the First-Line Treatment of Patients with Metastatic TNBC Who Are Not Candidates for Immunotherapy31.7.2026 08:30:00 CEST | Press release
Approval based on TROPION-Breast02 phase 3 trial results where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival Datroway now approved for two breast cancer indications in the EU Datroway® (datopotamab deruxtecan) has been approved in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinionof the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on result
Polpharma Biologics Announces FDA and EMA Acceptance for Review of PB016 Vedolizumab Biosimilar Candidate31.7.2026 08:30:00 CEST | Press release
Polpharma Biologics International AG today announces that the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have accepted for review the Biologics License Application (BLA) and Marketing Authorisation Application (MAA), respectively, for PB016, a proposed vedolizumab biosimilar candidate to Takeda’s reference product Entyvio®* (vedolizumab) lyophilized vial for intravenous (IV) administration for the treatment of adults with moderately to severely active ulcerative colitis and Crohn's disease. The BLA and MAA acceptances represent significant milestones in Polpharma Biologics' development program and underscore the company's commitment to advancing high-quality biosimilars and expanding global access to affordable biologic medicines. "FDA and EMA acceptances for review of our IV vedolizumab biosimilar candidate mark a major achievement for Polpharma Biologics and validate our deep scientific expertise in biosimilar development and manufacturing," said
SES: Disclosure of Share Buyback Transactions31.7.2026 07:30:00 CEST | Press release
In the time period from June 2, 2026 until and including June 23, 2026, a number of 213,167 shares were bought back within the framework of the share buyback of SES to meet obligations under SES’s Equity Based Compensation Plan (EBCP). Shares were bought back as follows: Day of purchase Aggregated volume in shares Daily weighted average acquisition price of shares (EUR) Market June 2, 2026 27,097 8.8727 DXE June 2, 2026 72,903 8.8556 ENX June 5, 2026 16,624 8.3723 DXE June 5, 2026 31,510 8.4266 ENX June 15, 2026 26,451 7.8423 XPAR June 17, 2026 26,812 7.3910 XPAR June 23, 2026 11,770 7.2200 XPAR The transactions in a detailed form are published on SES’s website: https://www.ses.com/investors/shareholder-information/share-buy-backs. Follow us on: Twitter | Facebook | YouTube | LinkedIn | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, busin
Half-Year Report on SES’s Liquidity Contract31.7.2026 07:30:00 CEST | Press release
Pursuant to the liquidity contract entered into by SES with BNP Paribas as of 7 April 2026, please see the below update on the progress of the liquidity services. When the liquidity services were implemented as of 7 April 2026, the following assets were in the liquidity account: € 2,500,000 As of 30 June 2026, the following assets appeared on the liquidity account: 228,186 shares; € 816,880. Over the period from 7 April 2026 to 30 June 2026, the following transactions were executed: 1,082 buy transactions; 1,308 sales transactions. Over this same period, the volumes traded represented: 1,093,335 shares and € 8,485,986 on the buy side; 873,399 shares and € 6,860,843 on the sell side. Follow us on: LinkedIn | Facebook | YouTube | X | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, businesses grow, and people stay connected—no matter where th
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
